-
摘要: 高血压是大众健康问题，中国成年人高血压患病率高达27.9%。尽管在过去30年间，中国高血压治疗与控制率显著提高，但总体水平仍较低，高血压知晓率仅为46.9%，而接受降压药物治疗的患者控制率也仅为37.6%。建设数字技术平台，将有助于实现高血压管理的规范化、信息化和智慧化，而数字疗法将显著提高药物与非药物治疗的降压效果，从而提高高血压控制率。未来还需要进一步加强数字产品的开发和研制，并对平台和疗法进行有效性验证，这一创新技术将在提升慢病管理的覆盖与效果等方面发挥重要作用。Abstract: Hypertension is a major public health problem. The current prevalence of hypertension in adult Chinese is 27.9%. Although in the past 30 years, the treatment and control of hypertension in China improved substantially, but remained at low level, with an awareness rate of 46.9% in patients with hypertension and a control rate of 37.6% in treated hypertensive patients. Digital platforms might help for the management of hypertension in the standardization of all procedures and in the use of information technology and artificial intelligence. Digital therapeutics, on the other hand, may help in the implementation of the current pharmacological and non-pharmacological antihypertensive therapies. Both digital techniques will probably improve control of hypertension eventually. However, there is still unmet need in the research and development of digital techniques, including clinical validation for effectiveness. Nonetheless, these innovative techniques might play a role in the improvement of the chronic disease management for both coverage and effectiveness.
-
Key words:
- hypertension /
- digital platforms /
- digital therapeutics /
- awareness rate /
- control rate
-
-
[1] Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015[J]. Circulation, 2018, 137(22): 2344-2356. doi: 10.1161/CIRCULATIONAHA.117.032380
[2] Beaney T, Schutte AE, Tomaszewski M, et al. May Measurement Month 2017: an analysis of blood pressure screening results worldwide[J]. Lancet Glob Health, 2018, 6(7): e736-e743. doi: 10.1016/S2214-109X(18)30259-6
[3] Chen X, Xu SK, Li Y, et al. May Measurement Month 2017: an analysis of blood pressure screening results in China-East Asia[J]. Eur Heart J Suppl, 2019, 21(Suppl D): D37-D39.
[4] Wang JG. Unique approaches to hypertension control in China[J]. Ann Transl Med, 2018, 6(15): 296. doi: 10.21037/atm.2018.07.27
[5] Chen X, Cheng YB, Wang JG. China nationwide screening and registry of primary aldosteronism in hypertensive patients[J]. J Hum Hypertens, 2021, 35(2): 157-161. doi: 10.1038/s41371-020-00458-4
[6] 王继光. 移动医疗与智慧医学[J]. 中华心血管病杂志, 2018, 46(3): 171-172.
[7] Park JB, Kario K, Wang JG. Systolic hypertension: an increasing clinical challenge in Asia[J]. Hypertens Res, 2015, 38(4): 227-236.
[8] Kario K, Harada N, Okura A. Digital Therapeutics in Hypertension: Evidence and Perspectives[J]. Hypertension, 2022: HYPERTENSIONAHA12219414. doi: 10.1161/HYPERTENSIONAHA.122.19414
[9] Kario K, Nomura A, Harada N, et al. A multicenter clinical trial to assess the efficacy of the digital therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial[J]. J Clin Hypertens(Greenwich), 2020, 22(9): 1713-1722.
[10] Kario K, Nomura A, Kato A, et al. Digital therapeutics for essential hypertension using a smartphone application: A randomized, open-label, multicenter pilot study[J]. J Clin Hypertens(Greenwich), 2021, 23(5): 923-934.
[11] Kario K, Nomura A, Harada N, et al. Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial[J]. Eur Heart J, 2021, 42(40): 4111-4122.
-
计量
- 文章访问数: 2481
- PDF下载数: 1170
- 施引文献: 0
下载: